Navigation Links
OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
Date:11/8/2010

, varied clinical pipeline, and growth prospects presents a compelling opportunity," said Ms. Burris.

Ms. Burris also sits on the board of directors of the Washington Biotechnology and BioMedical Association and the Executive Advisory Board of the Albers School of Business and Economics at Seattle University. She holds a Postgraduate Certificate in accounting and an MBA from Seattle University, a BS from George Mason University, and she has passed the CPA exam. About OncoGenex OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011; OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com. OncoGenex's Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning Ms. Burris' appointment and our anticipated product development activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Reports Third Quarter Financial Results
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
5. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
6. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
7. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
8. OncoGenex Reports Second Quarter Financial Results
9. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
10. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
11. OncoGenex Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SAN DIEGO , March 5, 2015  In ... Marketwired in Miami, FL on ... company are both of strong financial health and their ... as clinical research has indicated. Furthermore, Impeto prefers to have ... There are more than 40 articles written ...
(Date:3/5/2015)... Southlake, Texas (PRWEB) March 05, 2015 ... treatment of acute and chronic orthopedic conditions such ... runner’s knee, tennis elbow, and joint pain due ... also be administered during orthopedic surgeries to promote ... patented scientific advances in nearly pain-free bone marrow ...
(Date:3/4/2015)... , March 4, 2015 The UPMC Center ... 2015 Fellows in the Emerging Leaders in Biosecurity Initiative ... leaders in the field of biosecurity, UPMC has selected ... a wide array of backgrounds, including biological science, medicine, ... "With the vision and support of ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... report follows the broad definition of a biomarker ... and evaluated as an indicator of normal biological ... to a therapeutic intervention. Tests based on biomarkers ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... NEW YORK, Feb. 17, 2011 Reportlinker.com announces ... in its catalogue: Targeted Therapeutics- ... will Drive the Market ... Gene Therapy and Stem Cell Therapy will Drive ...
... to learn if your water source has hexavalent chromium ... request a water quality report, said NJIT Professor Taha ... engineers should be able to provide such a report ... levels may also be available. "In general, hexavalent ...
... the most effective weapons to stop the spread of cholera, ... since the devastating earthquake last year. A technique developed ... to test water sources that could be contaminated with the ... onto iron oxide nanoparticles and then added to a sample ...
Cached Biology Technology:Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market 2Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market 3Removal of hexavalent chromium from your drinking water 2Removal of hexavalent chromium from your drinking water 3Special sugar, nanoparticles combine to detect cholera toxin 2Special sugar, nanoparticles combine to detect cholera toxin 3
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) ... Global Market Overview" report to their offering. , ... ensure that an individual is who she/he is claiming to ... of a person,s unique physical characteristics, such as fingerprint, hand ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... Never underestimate the power of Mom when it comes ... explains how motherly influence could be even more effective ... Knowlden, a former doctoral student at UC and current ... Department, hopes his research can better prepare moms to ...
... release is available in German . ... global impacts of land use on the environment and help ... of the Helmholtz Centre for Environmental Research (UFZ) has created ... various indicators of land-use intensity, climate, environmental and socio-economic conditions, ...
... earthquakes, major traffic accidents, and terrorist attacks may ... extreme fear and helplessness for people that have ... This persistent and constant mental disorder caused by ... Can brain structural damage alter as symptoms ...
Cached Biology News:Internet helps ensure mother knows best when it comes to preventing childhood obesity 2Internet helps ensure mother knows best when it comes to preventing childhood obesity 3Global map provides new insights into land use 2Global map provides new insights into land use 3
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
... anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... dependent dilution. ICC: Use at an assay dependent ... - 10 ug/ml, this concentration is determined using ... weight: 40 kDa. Not tested in other applications. ...
Potassium Channel kv3.2...
Biology Products: